Skip to main content
Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.620
+0.110 (7.28%)
At close: Mar 9, 2026, 4:00 PM EDT
1.640
+0.020 (1.23%)
After-hours: Mar 9, 2026, 7:31 PM EDT

Autolus Therapeutics Revenue

Autolus Therapeutics had revenue of $21.19M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $51.13M, up 406.67% year-over-year. In the year 2024, Autolus Therapeutics had annual revenue of $10.12M with 496.00% growth.

Revenue (ttm)
$51.13M
Revenue Growth
+406.67%
P/S Ratio
8.43
Revenue / Employee
$78,658
Employees
650
Market Cap
431.15M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202410.12M8.42M496.00%
Dec 31, 20231.70M-4.66M-73.30%
Dec 31, 20226.36M4.03M172.96%
Dec 31, 20212.33M615.00K35.86%
Dec 31, 20201.72M-1.19M-41.02%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Sep 30, 2018 Pro Pro Pro
Sep 30, 2017 Pro Pro Pro
Sep 30, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Niagen Bioscience 129.42M
Sutro Biopharma 105.65M
Enanta Pharmaceuticals 66.98M
Crescent Biopharma 10.84M
PureTech Health 6.39M
Immutep 5.28M
Upstream Bio 2.80M
Revenue Rankings

AUTL News

More News